Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial

    July 2023 in “ Pediatric Dermatology ”
    Maria Hordinsky, Adelaide A. Hebert, Melinda Gooderham, Ohsang Kwon, Nikolay N. Murashkin, Hong Fang, Kazutoshi Harada, Ernest H. Law, Dalia Wajsbrot, Liza Takiya, Samuel H. Zwillich, Robert Wołk, Helen Tran
    TLDR Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
    The study titled "Efficacy and safety of ritlecitinib in adolescents with alopecia areata" presents results from the ALLEGRO phase 2b/3 randomized, double-blind, placebo-controlled trial. It evaluates the effectiveness and safety of ritlecitinib in treating adolescents with alopecia areata. The trial included a significant number of participants, enhancing the reliability of the findings. The results indicate that ritlecitinib is effective in promoting hair regrowth in adolescents with alopecia areata, with a favorable safety profile. These findings suggest that ritlecitinib could be a promising treatment option for this condition in the adolescent population.
    Discuss this study in the Community →

    Research cited in this study

    9 / 9 results